In early 2026, the Hyperlipidemia Drug Market is estimated to be valued at $26.34 billion, driven by a massive pivot toward "Durable Lipid Control." This year, the industry is buzzing over "siRNA Gene-Silencing," with therapies like inclisiran receiving expanded approvals for first-line use. This innovation is a primary driver for the market, as it allows patients to manage their LDL...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
คลิกดาวน์โหลด
china 
thai
English
French
Spanish
Portuguese
Italiano
Romaian
Portuguese (Brazil)